Concepedia

Dana F. Chace

DF

Statistics

Publications

18

Citations

4.1K

H-Index

16

Active since

1993

Affiliations

Bristol-Myers Squibb (United States)(Current)

Seagen (United States)

Bristol-Myers Squibb (Germany)

Dana F. Chace is an author at Bristol-Myers Squibb (United States) specializing in oncology, cancer immunotherapy, and cancer immunology.

Publications per year

1993–2004

18

Publications

18

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations

, , +17

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations

, , +14

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 921 citations

, , +11

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Alan F. Wahl, Kerry Klussman, Jennifer Thompson et al. · PubMed · 2002 · 212 citations

, , +16

Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates

Che‐Leung Law, Charles G. Cerveny, Kristine A. Gordon et al. · Clinical Cancer Research · 2004 · 118 citations

, , +17

1–5 of 18